Atherogenesis: The role of inflammation and infection

Histopathology

Volumn 50, Issue 5, 2007, Pages 535-546

  Mahmoudi, M ^a   Curzen, N ^a   Gallagher, P J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ACE inhibitors; Atherosclerosis; Infectious agents; Lipid lowering agents; Proinflammatory cytokines

Indexed keywords

AMOXICILLIN; AMYLOID A PROTEIN; ATORVASTATIN; AZITHROMYCIN; C REACTIVE PROTEIN; CAPTOPRIL; CELL ADHESION MOLECULE; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; METRONIDAZOLE; MEVINOLIN; OMEPRAZOLE; PADGEM PROTEIN; PERINDOPRIL; PLACEBO; PRAVASTATIN; QUINAPRIL; RAMIPRIL; ROXITHROMYCIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANGINA PECTORIS; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HISTOLOGY; HUMAN; INFECTION; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 33947694613     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02503.x     Document Type: Review

References (98)

1. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. 2005; 352; 1685-1695.
2. Virmani R, Kolodgie D, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2000; 20; 1262-1275.
3. Burke AP, Farb A, Malcolm GT et al. Coronary risk factors and plaque morphology in men with coronary disease who die suddenly. N. Engl. J. Med. 1997; 336; 1276-1282.
4. Farb A, Burke AP, Tang Al et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden cardiac death. Circulation 1996; 93; 1354-1363.
5. Burke AP, Kolodgie D, Farb A et al. Healed plaque ruptures and sudden cardiac death. Evidence that sub-clinical rupture has a role in plaque progression. Circulation 2001; 103; 935-940.
6. Henriques de Gouveia R, van der Wal AC, van der Loos CM, Becker AE. Sudden unexpected death in young adults. Discrepancies between iniation of acute plaque complications and the onset of acute coronary death. Eur. Heart J. 2002; 23; 1433-1440.
7. Luscher TF, Barton M. Biology of the endothelium. Clin. Cardiol. 1997; 20 (Suppl. II); II-3-II-10.
8. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 2001; 12; 383-389.
9. Drexler H. Factors involved in the maintenance of endothelial function. Am. J. Cardiol. 1998; 82; 3S-4S.
10. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000; 87; 840-844.
11. Laursen JB, Somers M, Kurz S et al. Endothelial regulation of vasomotion in apo-E-deficient mice: implications for interactions between peroxynitrite and tetrahydro-biopterin. Circulation 2001; 103; 1282-1288.
12. Cooke JP. Does ADMA cause endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2000; 20; 2032-2037.
13. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999; 340; 115-126.
14. Li H, Cybulsky MI, Gimbrone MA et al. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler. Thromb. 1993; 13; 197-204.
15. Gu L, Okada Y, Clinton S et al. Absence of monocyte chemo-attractant protein-1 reduces atherosclerosis in low density lipoprotein deficient mice. Mol. Cell. 1998; 2; 275-281.
16. Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2 mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394; 894-897.
17. Rajavashisth TB, Andalibi A, Territo MC et al. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low density lipoproteins. Nature 1990; 344; 254-257.
18. Qiao JH, Tripathi J, Mishra NK et al. Role of macrophage colony stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am. J. Pathol. 1997; 150; 1687-1699.
19. Mach F, Sauty A, Iarossi A et al. Differential expression of three T lymphocyte activating CXC chemokines by human atheroma associated cells. J. Clin. Invest. 1999; 104; 1041-1050.
20. Boring L, Gosling J, Cleary M et al. Decreased leision formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394; 894-897.
21. Kunjathoor VV, Febraio M, Podrez EA et al. Scavenger receptors class A-I/II and CD36 are the principle receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 2002; 277; 49982-49988.
22. Yoshida H, Kondraatenko N, Green S et al. Identification of the lectin-like receptor for oxidised low density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem. J. 1998; 334; 9-13.
23. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105; 1135-1153.
24. Libby P. Inflammation in atherosclerosis. Nature 2002; 420; 868-874.
25. Verma S, Wang CH, Li SH et al. A self fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106; 913-919.
26. Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105; 1890-1896.
27. Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107; 1783-1790.
28. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 2000; 321; 199-204.
29. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004; 350; 1387-1397.
30. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109; 1955-1959.
31. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein associated phopholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities [ARIC] study. Circulation 2004; 109; 837-842.
32. Toss H, Lindahl B, Siegbahn A et al. Prognostic influence of increased fibrinogen C-reactive protein levels in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease [FRISC] Study Group. Circulation 1997; 96; 4204-4210.
33. Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease [FRISC] Study Group. N. Engl. J. Med. 2000; 343; 1139-1147.
34. James SK, Armstrong P, Barnathan E et al. GUSTO-IV ACS investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J. Am. Coll. Cardiol. 2003; 41; 916-924.
35. Zairis MN, Ambrose JA, Manousakis SJ et al. The impact of plasma levels of C-reactive protein, lipoprotein {a} and homo-cysteine on the long term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study. J. Am. Coll. Cardiol. 2002; 40; 1375-1382.
36. Zouridakis E, Avanzas P, Arroyo-Espliguero R et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110; 1747-1753.
37. Poston RN, Haskard DO, Coucher JR et al. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am. J. Pathol. 1992; 140; 665-673.
38. Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the ARIC study. Circulation 1997; 96; 4219-4225.
39. Ridker PM, Hennekens CH, Roitman-Johnson B et al. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351; 88-92.
40. Inokubo Y, Hanada H, Ishizaka H et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 2001; 141; 211-217.
41. Curzen NP, Fox KM. Do ACE inhibitors modulate atherosclerosis? Eur. Heart J. 1997; 18; 1530-1535.
42. Mancini GBJ, Henry GC, Macaya C et al. ACE inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation 1994; 94; 258-265.
43. Curzen NP, Timmis A. Endothelial function in heart failure. Chapter 3. In Coats A ed. Frontiers in heart failure. London: Churchill Livingstone 1997; 25-40.
44. Koh KK, Bui MN, Hathaway J et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am. J. Cardiol. 1999; 83; 327-331.
45. Kofler S, Nickel T, Weiss S. The role of cytokines in cardiovascular disease: a focus on endothelial responses to inflammation. Clin. Sci. 2005; 108; 205-213.
46. The SOLVD investigators. Effect of enalopril on survival in patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327; 685-691.
47. Rutherford JD, Pfeffer MA, Moye LA et al. On behalf of the SAVE investigators. Effects of captopril on ischaemic events after MI. Results of the SAVE trial. Circulation 1994; 90; 1731-1738.
48. The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N. Engl. J. Med. 2000; 342; 145-153.
49. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial [the EUROPA study]. Lancet 2003; 362; 782-788.
50. Scandinavian Simvastatin Survival Study group. Randomised trial of cholestrol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study [4S]. Lancet 1994; 344; 1383-1389.
51. Shepherd J, Cobbe SM, Ford I et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 1995; 333; 1301-1307.
52. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholestrol lowering with simvastatin in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360; 7-22.
53. The Long-Term Intervention with Pravastatin in Ischaemic Disease [LIPID] Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholestrol levels. N. Engl. J. Med. 1998; 339; 1349-1357.
54. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholestrol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm [ASCOT-LLA]. Lancet 2003; 361; 1149-1158.
55. Sacks FM, Pfeffer MA, Moye LA et al. for the Cholestrol and Recurrent Events Trial investigators. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholestrol levels. N. Engl. J. Med. 1996; 335; 1001-1009.
56. Laufs U, La Fata V, Plutzky J et al. Upregulation of endothelial nitric oxide synthase by HMG-COA reductase inhibitors. Circulation 1998; 97; 1129-1135.
57. Laufs U, Liao JK. Post transcriptional regulation of endothelial nitric oxide sunthase mRNA activity stability by Rho GTPase. J. Biol. Chem. 1998; 273; 24266-24271.
58. Laufs U, La Fata V, Liao JK. Inhibition of HMG-COA reductase blocks hypoxia mediated down regulation of endothelial nitric oxide synthase. J. Biol. Chem. 1997; 272; 31725-31729.
59. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, an HMG-COA reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104; 376-379.
60. Wassmann S, Faul A, Hennen B et al. Rapid effect of HMG-COA reductase inhibition on coronary endothelial function. Circ. Res. 2003; 93; 98-103.
61. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normo-cholestrolemic rats. Arterioscler. Thromb. Vasc. Biol. 1999; 19; 2894-2900.
62. Bustos C, Hernandez-Presa MA, Ortega M et al. HMG-COA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 1998; 32; 2027-2034.
63. Aikawa M, Rabkin E, Sugiyama S et al. An HMG-COA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metallo-proteinases and tissue factor in vivo and in vitro. Circulation 2001; 103; 276-283.
64. Albert MA, Danielson E, Rifai N et al. for the PRINCE investigators. Effect of statin therapy on CRP levels: the Pravastatin Inflammation/CRP Evaluation [PRINCE]. JAMA 2001; 286; 64-70.
65. Ridker PM, Rifai N, Clearfield M et al. for the Air Force/Texas Coronary Athero-sclerosis Prevention Study Investigators. Measurement of CRP for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001; 344; 1959-1965.
66. Kinlay S, Schwartz GG, Olsson AG et al. for the Myocardial Ischaemia Reduction with Aggressive Cholestrol Lowering [MIRACL] study investigators. High dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108; 1560-1566.
67. Nissen SE, Tuzcu EM, Schoenhagen P et al. for the Reversal of Atherosclerosis with Aggressive Lipid lowering [REVERSAL] investigators. Statin therapy, LDL-cholesterol, CRP, and coronary artery disease. N. Engl. J. Med. 2005; 352; 29-38.
68. Ridker PM, Rifai N, Pfeffer MA et al. for the Cholesterol and Recurrent Events [CARE] investigators. Long term effects of pravastatin on plasma concentration of CRP. Circulation 1999; 100; 230-235.
69. Ridker PM, Cannon CP, Morrow D et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] investigators. CRP levels and outcomes after statin therapy. N. Engl. J. Med. 2005; 352; 20-28.
70. Muhlestein JB, Hammond EH, Carlquist JF et al. Increased incidence of chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 1996; 27; 1555-1561.
71. Danesh J, Applby P. Persistent infection and vascular disease: a systematic review. Exp. Opin. Invest. Drugs 1998; 7; 671-691.
72. Adam E, Probtsfield JL, McCollum CH et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2; 291-293.
73. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a chlamydia, TWAR, with chronic heart disease and acute myocardial infarction. Lancet 1988; 2; 983-986.
74. Havlik RJ, Blackwelder WC, Kaslow R et al. Unlikely association between clinically apparent herpesvirus infection and coronary incidence at older ages. Arterisclerosis 1989; 9; 877-880.
75. Weiss SW, Robin PM, Gaydos CA et al. failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J. Infect. Dis. 1996; 173; 957-963.
76. Folsom AR, Nieto FJ, Sorlie P et al. for the Atherosclerosis Risk in Communities [ARIC] Study Investigators. Helicobacter pylori seropositivity and coronary heart disease incidence. Circulation 1998; 98; 845-850.
77. Adler SP, Hur JK, Wang JB et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J. Infect. Dis. 1998; 177; 209-212.
78. Ridker PM, Hennekens CH, Stampfer MJ et al. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98; 2796-2799.
79. Hajjar DP, Pomerantz KB, Falcone DJ et al. Herpes simplex virus infection in human arterial cells: implication in atherosclerosis. J. Clin. Invest. 1987; 80; 1317-1321.
80. Zhou YF, Guette E, Yu ZX et al. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J. Clin. Invest. 1996; 98; 2129-2138.
81. Vercellotti GM. Effect of viral activation of the vessel wall on inflammation and thrombosis. Blood Coagul. Fibrinolysis 1998; 9 (Suppl. 2); S3-S6.
82. Visser MR, Tracy PB, Vercellotti GM et al. Enhanced thrombin generation and platelet binding on herpes simplex virus infected endothelium. Proc. Natl Acad. Sci. USA 1988; 85; 8227-8230.
83. Key NS, Vercellotti GM, Winkelmann JC et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc. Natl Acad. Sci. USA 1990; 87; 7095-7099.
84. Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-1 on the surface fibroblasts infected with cytomegalovirus. Immunology 1993; 78; 405-412.
85. Span AHM, Mullers W, Miltenburg AHM et al. Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers. Immunology 1991; 72; 355-360.
86. Zhou YF, Yu ZX, Wanshsawad C et al. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta receptor. Biochem. Biophys. Res. Commun. 1999; 256; 608-613.
87. Levine AJ. p53, the cellular gatekeper for growth and division. Cell 1997; 88; 323-331.
88. Zhou YF, Shou M, Guetta E et al. Cytomegalovirus infection of rats increases neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999; 100; 1569-1575.
89. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999; 100; e20-e28.
90. Zhu J, Quyyumi AA, Norman JE et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am. J. Cardiol. 2000; 85; 140-146.
91. Zhu J, Nieto FJ, Horne BD et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103; 45-51.
92. Stone AFM, Mendall MA, Kaski JC et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes. The South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina [STAMINA]. Circulation 2002; 106; 1219-1223.
93. Gurfinkerl E, Bozovich G, Beck E et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur. Heart J. 1999; 20; 121-127.
94. Zahn R, Schneider S, Frilling B et al. Antibiotic therapy after acute myocardial infarction: a prospective randomised study. Circulation 2003; 107; 1253-1259.
95. Cercek B, Shah PK, Noc M et al. for the AZACS investigators. Effect of short term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome [AZACS] trial: a randomised controlled trial. Lancet 2003; 361; 809-813.
96. Grayston JT, Kronmal RA, Jackson LA et al. Azithromycin for the secondary prevention of coronary events. N. Engl. J. Med. 2005; 352; 1637-1645.
97. Cannon CP, Braunwald E, McCabe CH et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N. Engl. J. Med. 2005; 352; 1646-1654.
98. Anderson JL. Infections, antibiotics and atherothrombosis. End of the road or new beginnings. N. Engl. J. Med. 2005; 352; 1706-1709.